GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Lumos Pharma Inc (FRA:4NX1) » Definitions » Accounts Receivable

Lumos Pharma (FRA:4NX1) Accounts Receivable : €0.00 Mil (As of Mar. 2024)


View and export this data going back to 2011. Start your Free Trial

What is Lumos Pharma Accounts Receivable?

Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Lumos Pharma's accounts receivables for the quarter that ended in Mar. 2024 was €0.00 Mil.

Accounts receivable can be measured by Days Sales Outstanding. Lumos Pharma's Days Sales Outstanding for the quarter that ended in Mar. 2024 was 0.00.

In Ben Graham's calculation of Net-Net Working Capital, accounts receivable are only considered to be worth 75% of book value. Lumos Pharma's Net-Net Working Capital per share for the quarter that ended in Mar. 2024 was €1.38.


Lumos Pharma Accounts Receivable Historical Data

The historical data trend for Lumos Pharma's Accounts Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lumos Pharma Accounts Receivable Chart

Lumos Pharma Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Accounts Receivable
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Lumos Pharma Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Accounts Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Lumos Pharma Accounts Receivable Calculation

Accounts Receivable is money owed to a business by customers and shown on its Balance Sheet as an asset.


Lumos Pharma Accounts Receivable Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's accounts receivables are being managed.

Lumos Pharma's Days Sales Outstanding for the quarter that ended in Mar. 2024 is calculated as:

Days Sales Outstanding
=Accounts Receivable/Revenue*Days in Period
=0/0.152*91
=0.00

2. In Ben Graham's calculation of Net-Net Working Capital (NNWC), Lumos Pharma's accounts receivable are only considered to be worth 75% of book value:

Lumos Pharma's Net-Net Working Capital Per Share for the quarter that ended in Mar. 2024 is calculated as:

Net-Net Working Capital Per Share
=(Cash And Cash Equivalents+0.75 * Accounts Receivable+0.5 * Total Inventories-Total Liabilities
-Preferred Stock-Minority Interest)/Shares Outstanding (EOP)
=(21.325+0.75 * 0+0.5 * 0-9.788
-0-0)/8.35739
=1.38

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net receivables tells us a great deal about the different competitors in the same industry. In competitive industries, some attempt to gain advantage by offering better credit terms, causing increase in sales and receivables.

If company consistently shows lower % Net receivables to gross sales than competitors, then it usually has some kind of competitive advantage which requires further digging.

Average Days Sales Outstanding is a good indicator for measuring a company's sales channel and customers. A company may book great revenue and earnings growth but never receive payment from their customers. This may force a write-off in the future and depress future earnings.


Lumos Pharma Accounts Receivable Related Terms

Thank you for viewing the detailed overview of Lumos Pharma's Accounts Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.


Lumos Pharma (FRA:4NX1) Business Description

Traded in Other Exchanges
Address
4200 Marathon Boulevard, Suite 200, Austin, TX, USA, 78756
Lumos Pharma Inc is a biopharmaceutical company that develops treatments for cancer and rare diseases. It carries out both clinical-stage and preclinical research on a range of molecules that help the immune system fight off cancer cells. The treatments are available orally and can be used in conjunction with other cancer therapies. The company also researches an Ebola vaccine. Lumos contracts with manufacturing organizations to make their treatments, engages in partnerships with pharmaceutical companies, and operates primarily in the United States.

Lumos Pharma (FRA:4NX1) Headlines

No Headlines